Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sMRI-guided Proton Therapy and Bevacizumab for Recurrent Glioblastoma
NCT05284643Recruiting
- Sponsor
- University of Miami
- Start
- Sep 2022
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Open-label trial in glioblastoma (GBM) (2 cohorts), sponsored by University of Miami. Primary endpoints: Percentage of patients for whom sMRI-guided therapy is technically successful at 60 days and Incidence of Grade 3 irreversible or any Grade 4/5 neurologic toxicity at 6 months. Started Sep 2022; status: recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05284643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284643.